Drug Trial Radar · NCT07545395
Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Mar 13, 2026
Primary completion
Dec 30, 2027
Study completion Mar 30, 2028
Sponsor
- Lead sponsor
- Suzhou Alphamab Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purposes of this open-label, multicenter III clinical trial are to evaluate the safety and efficacy of long-term preventive treatment with KN057 in Haemophilia A or B patients with or without inhibitors, and to assess the pharmacokinetic characteristics of the new and old processes KN057. The participants in Part PK will be randomly assigned to Old process Group or New process Group in a 1:1 ratio. The participants in Old process Group will receive old process KN057 prophylaxis for the first 26 weeks and new process KN057 prophylaxis for the following 26 weeks. The participants in New process Group will receive new process KN057 prophylaxis for both the first 26 weeks and the last 26 weeks. The participants in Part non-PK will be non-randomized and treated with new process KN057 for 52 weeks prophylaxis after enrollment. Priority screening and enrollment of participants who have participated in the KN057-A-301 or KN057-A-302 study.
Conditions
- Hemophilia A or B
Interventions
KN057Drug
KN057 will be administered subcutaneously once a week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TEAE.Time frame: Up to 12/26/56 weeks.
- Incidence of TEAE related to the experimental drug.Time frame: Up to 12/26/56 weeks.
- Incidence of SAE.Time frame: Up to 12/26/56 weeks.
- Incidence of thromboembolic events.Time frame: Up to 12/26/56 weeks.
- Incidence of TMA and DIC.Time frame: Up to 12/26/56 weeks.
- Incidence of hypersensitivity type reactions.Time frame: Up 12/26/56 weeks.
- Incidence of injection site reactions.Time frame: Up to 12/26/56 weeks.
- Incidence of clinically significant laboratory value abnormalities.Time frame: Up to 12/26/56 weeks.
- Number of participants with clinically significant changes from baseline in electrocardiograms.Time frame: Up to 12/26/56 weeks.
- Number of participants with clinically significant changes from baseline in vital signs.Time frame: Up to 12/26/56 weeks.
- Number of participants with clinically significant changes from baseline in physical exam.Time frame: Up to 12/26/56 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.